About this trial
The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus in Brazil. The expectation is to include at least 80 patients over six months, with a follow-up of 90 days from inclusion, through contact via decentralized visits.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Men and women aged ≥ 18 years with confirmed MPOX infection.
Disqualifiers
Inability to provide informed consent;
Patient who, judging by the study team, does not have a condition for decentralized follow-up
Trial population
Individuals who have risk factors for mpox infection in Brazil.
Trial design
Cohort
Prospective
Treatments tested in this trial
Viral genomic
Diagnostic testEvaluation of mpox viral genomic
Untargeted Metabolomics
Diagnostic testEvaluation of metabolomics of the total plasma, oropharynx, and skin samples.
Treatment groups
Trial outcomes
Primary outcomes
Composed of incidence of rash, fever, adenopathy, general pain, chills, weakness, occurrence of hospitalization, and neurological repercussions
symptoms' incidence in participants with mpox infection
Secondary outcomes
Death
Incidence of death
Hospitalizations
Incidence of hospitalization
Untargeted metabolomics of total plasmas and skin lesion
Changes among visits of Immune-metabolomics responses related to symptoms' incidence
Viral genomic
Evaluation of the pattern of viral genome of the mpox virus circulation in Brazil
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Hospital Israelita Albert Einstein
Lead sponsor
Ministry of Health, Brazil
Collaborator